Make Your Voice Heard on MS Treatment

The Institute for Clinical and Economic Review (ICER) is currently conducting a review of disease-modifying therapies for relapsing-remitting and primary-progressive forms of multiple sclerosis. Insurers may use ICER recommendations to develop or change their approved drug lists, which could potentially improve or restrict access to MS medications for people living with MS. To ensure that people living with MS have direct input into their analysis of the use and effectiveness of disease-modifying therapies, the MS Coalition contacted ICER. As you may know, the Multiple Sclerosis Association of America (MSAA) is a member of the MS Coalition.

The MS Coalition is a not-for-profit organization through which nine (9) independent MS organizations collaborate to improve the quality of life for those living with or affected by MS. Together, we strive to address advocacy issues that impact access to care, develop and disseminate needed informational and programmatic resources for the MS community and leverage our collective strength to promote greater funding opportunities for MS research.

As a result of our discussions, a joint survey has been developed to gain valuable patient input into the use of these drugs.

If you are a person diagnosed with MS, whether or not you are taking disease-modifying treatment, your experience matters. In just five to ten minutes, you can provide valuable input by completing this short, anonymous survey. Your participation is vital to this effort to determine whether we can help improve your access to and satisfaction with MS drug therapy.

Please let us know how you feel about disease-modifying medication(s) for MS. The survey will be active from August 31, 2016 through September 14, 2016.

This survey is limited to those of 21 years or older.